[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG10202110144TA - Compositions and methods for inhibiting arginase activity - Google Patents

Compositions and methods for inhibiting arginase activity

Info

Publication number
SG10202110144TA
SG10202110144TA SG10202110144TA SG10202110144TA SG 10202110144T A SG10202110144T A SG 10202110144TA SG 10202110144T A SG10202110144T A SG 10202110144TA SG 10202110144T A SG10202110144T A SG 10202110144TA
Authority
SG
Singapore
Prior art keywords
compositions
methods
arginase activity
inhibiting arginase
inhibiting
Prior art date
Application number
Other languages
English (en)
Inventor
Matthew Gross
Susanne Steggerda
Weiqun Li
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of SG10202110144TA publication Critical patent/SG10202110144TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10202110144T 2015-06-23 2016-06-23 Compositions and methods for inhibiting arginase activity SG10202110144TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562183524P 2015-06-23 2015-06-23

Publications (1)

Publication Number Publication Date
SG10202110144TA true SG10202110144TA (en) 2021-10-28

Family

ID=57585664

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202110144T SG10202110144TA (en) 2015-06-23 2016-06-23 Compositions and methods for inhibiting arginase activity

Country Status (17)

Country Link
US (4) US10143699B2 (fr)
EP (1) EP3313410A4 (fr)
JP (2) JP2018520352A (fr)
KR (1) KR20180021117A (fr)
CN (1) CN107921051A (fr)
AU (1) AU2016281620B2 (fr)
CA (1) CA2990192A1 (fr)
EA (1) EA201890113A1 (fr)
IL (1) IL256352A (fr)
MA (1) MA42269A (fr)
MX (1) MX2017016868A (fr)
MY (1) MY192605A (fr)
PH (1) PH12017502391A1 (fr)
SG (1) SG10202110144TA (fr)
UA (1) UA123700C2 (fr)
WO (1) WO2016210106A1 (fr)
ZA (1) ZA201800328B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ603364A (en) 2010-04-22 2015-06-26 Mars Inc Inhibitors of arginase and their therapeutic applications
SI2632927T1 (sl) 2010-10-26 2016-08-31 Mars, Incorporated Boronati kot inhibitorji arginaze
MX2017016868A (es) 2015-06-23 2018-09-06 Calithera Biosciences Inc Composiciones y metods para inhibir actividad de arginasa.
KR102434308B1 (ko) 2015-10-30 2022-08-19 칼리테라 바이오사이언시즈, 인코포레이티드 아르기닌 활성 억제용 조성물 및 방법
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
MA46793A (fr) 2016-11-08 2019-09-18 Calithera Biosciences Inc Polythérapies faisant appel à un inhibiteur d'arginase
SG10201911243WA (en) 2016-12-22 2020-02-27 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
CN108794517B (zh) * 2017-04-27 2021-03-30 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途
BR112019023582A2 (pt) 2017-05-12 2020-06-02 Calithera Biosciences Inc. Método de preparar (3r,4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida
WO2019000163A1 (fr) * 2017-06-26 2019-01-03 余祖江 Utilisation d'arginine dans la préparation d'un médicament antitumoral
WO2019120296A1 (fr) * 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Composés hétérocycliques utilisés en tant qu'inhibiteurs de l'arginase
BR112020015973A2 (pt) 2018-02-17 2020-12-15 Astrazeneca Ab Inibidores de arginase e métodos para o seu uso
IL276813B2 (en) * 2018-03-05 2024-09-01 Arcus Biosciences Inc History of 4-substituted 5-amino-octahydrocyclopenta[c]pyrrole-5-carboxylic acid, their pharmaceutical combinations and their use for the treatment of diseases
CA3094939A1 (fr) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Derives de piperidine dipeptidiques
WO2019205979A1 (fr) * 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 Dérivé d'acide aminé non naturel, composition pharmaceutique le contenant, son procédé de préparation et son utilisation
PL3840837T3 (pl) 2018-08-22 2024-08-19 Astrazeneca Ab Inhibitory arginazy i sposoby ich zastosowania
US20220016143A1 (en) * 2018-11-16 2022-01-20 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
WO2020104626A1 (fr) * 2018-11-21 2020-05-28 Black Belt Tx Ltd Inhibiteurs de l'arginase
EP3917936A4 (fr) * 2019-02-06 2022-12-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Acides alkylboroniques en tant qu'inhibiteurs d'arginase
KR20210126044A (ko) * 2019-02-08 2021-10-19 아스트라제네카 아베 아르기나제 저해제 및 이의 사용 방법
US10967020B2 (en) * 2019-04-05 2021-04-06 King Saud University Method of synthesizing custard apple peel nanoparticles
CN112110944B (zh) * 2019-06-21 2022-02-11 南京谷睿生物科技有限公司 一种化合物及其制备方法和应用
WO2021014380A1 (fr) * 2019-07-23 2021-01-28 Astrazeneca Ab Inhibiteurs d'arginase et procédés d'utilisation associés
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
WO2023191116A2 (fr) 2022-01-21 2023-10-05 Opiyo Sammy Oyoo Procédés améliorés faisant appel à la suramine et compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
EP1348427B1 (fr) 1997-07-29 2008-04-09 Alcon Laboratories, Inc. Compositions ophtalmologiques contenant des polymères de galactomannane et du borate
EP1049660A1 (fr) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions et procedes pour inhiber l'activite de l'arginase
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
AU2001275870A1 (en) * 2000-07-06 2002-01-21 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (fr) 2003-06-02 2004-12-02 Catherine Adele O'brien Amelioration de l'immunite contre le cancer par l'intermediaire de l'inhibition de l'arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2005014046A2 (fr) 2003-08-07 2005-02-17 Allergan, Inc. Compositions d'administration d'agents therapeutiques dans les yeux et leurs methodes d'elaboration et d'utilisation
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2007005620A2 (fr) 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: traitement cible du vieillissement cardiaque et de l'insuffisance cardiaque
WO2009008415A1 (fr) 2007-07-12 2009-01-15 Sanyo Denki Co., Ltd. Ventilateur axial double à inversion/rotation
LT2389352T (lt) * 2009-01-26 2019-06-10 The Trustees Of The University Of Pennsylvania Arginazės inhibitoriai ir naudojimo būdai
NZ603364A (en) 2010-04-22 2015-06-26 Mars Inc Inhibitors of arginase and their therapeutic applications
SI2632927T1 (sl) * 2010-10-26 2016-08-31 Mars, Incorporated Boronati kot inhibitorji arginaze
CA2824599C (fr) 2010-12-31 2020-03-10 Corridor Pharmaceuticals, Inc. Inhibiteurs de l'arginase et leurs procedes d'utilisation
CN104244932B (zh) 2011-10-19 2017-02-22 马尔斯公司 精氨酸酶抑制剂和其治疗应用
ES2627347T3 (es) 2011-10-20 2017-07-27 Glaxosmithkline Llc Aza-heterociclos bicíclicos sustituidos y análogos como moduladores de sirtuina
US9200011B2 (en) 2012-04-18 2015-12-01 Mars, Incorporated Ring constrained analogs as arginase inhibitors
BR112016009200A8 (pt) 2013-10-25 2020-03-24 Pharmacyclics Llc uso de um inibidor de btk e um inibidor imune do ponto de verificação
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
CN107405404A (zh) 2015-03-20 2017-11-28 塞米·欧尤·奥皮约 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
MX2017016868A (es) 2015-06-23 2018-09-06 Calithera Biosciences Inc Composiciones y metods para inhibir actividad de arginasa.

Also Published As

Publication number Publication date
US10143699B2 (en) 2018-12-04
US20180360860A1 (en) 2018-12-20
CA2990192A1 (fr) 2016-12-29
JP2021185146A (ja) 2021-12-09
EP3313410A4 (fr) 2019-01-02
US20190343852A1 (en) 2019-11-14
AU2016281620A1 (en) 2018-02-15
US20160375044A1 (en) 2016-12-29
ZA201800328B (en) 2018-12-19
JP2018520352A (ja) 2018-07-26
WO2016210106A1 (fr) 2016-12-29
EP3313410A1 (fr) 2018-05-02
MX2017016868A (es) 2018-09-06
KR20180021117A (ko) 2018-02-28
MA42269A (fr) 2018-05-02
IL256352A (en) 2018-02-28
AU2016281620B2 (en) 2021-07-22
PH12017502391A1 (en) 2018-06-25
US10398714B2 (en) 2019-09-03
US20210077510A1 (en) 2021-03-18
EA201890113A1 (ru) 2018-07-31
MY192605A (en) 2022-08-29
CN107921051A (zh) 2018-04-17
US10905701B2 (en) 2021-02-02
UA123700C2 (uk) 2021-05-19

Similar Documents

Publication Publication Date Title
IL288225A (en) Preparations and methods for preventing arginase activity
IL267532B (en) Preparations and methods for inhibiting arginase activity
ZA201800328B (en) Compositions and methods for inhibiting arginase activity
HK1257295A1 (zh) 用於免疫腫瘤學的組合物和方法
GB201513304D0 (en) Compositions and Methods
HK1245158A1 (zh) 阿吡莫德組合物及其使用方法
HK1252911A1 (zh) 用於抑制可溶生物分子的生物活性的組合物以及方法
HK1254550A1 (zh) 用於抑制β-內酰胺酶的組合物和方法
IL252191A0 (en) Compositions and methods for modulating at2r activity
GB201512996D0 (en) Compositions and methods
GB201514413D0 (en) Compositions and methods
GB201521083D0 (en) Compositions for treatment and methods thereof
GB201518167D0 (en) Methods and compositions
GB201514415D0 (en) Compositions and methods